Rongtai health(SH:603579)2023-10-27 16:00Financial Performance - The company's operating revenue for Q3 2023 was approximately ¥408.17 million, a decrease of 11.44% compared to the same period last year[3]. - Net profit attributable to shareholders of the listed company reached approximately ¥46.82 million, an increase of 19.13% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was approximately ¥38.61 million, up 29.38% from the previous year[3]. - Basic earnings per share for the quarter were ¥0.35, reflecting a 16.67% increase compared to the same period last year[5]. - Total revenue for the first three quarters of 2023 was CNY 1,298,074,815.73, a decrease of 17% compared to CNY 1,562,236,538.61 in the same period of 2022[20]. - Net profit for the first three quarters of 2023 was CNY 152,477,626.53, an increase of 21% from CNY 126,203,740.32 in the same period of 2022[21]. - Earnings per share for the first three quarters of 2023 were CNY 1.13, compared to CNY 0.94 in the same period of 2022[22]. - The total comprehensive income for the first three quarters of 2023 was CNY 200,265,076.43, compared to CNY 124,702,935.30 in the same period of 2022[22]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥3.29 billion, a decrease of 4.04% from the end of the previous year[5]. - Total liabilities as of the end of Q3 2023 amounted to CNY 1,283,371,531.81, a decrease from CNY 1,553,734,654.79 at the end of Q3 2022[20]. - Total equity as of the end of Q3 2023 was CNY 2,002,225,578.68, an increase from CNY 1,870,090,507.23 at the end of Q3 2022[20]. - As of September 30, 2023, the company's total current assets decreased to RMB 2,064,140,891.69 from RMB 2,270,578,335.21 at the end of 2022, representing a decline of approximately 9.1%[14]. - The total assets of the company decreased to RMB 3,285,597,110.49 from RMB 3,423,825,162.02, a decline of approximately 4.0%[16]. Cash Flow - The company reported a net cash flow from operating activities of approximately ¥145.61 million for the year-to-date, an increase of 5.42%[3]. - In the first three quarters of 2023, the cash inflow from operating activities was CNY 1,299,392,319.74, a decrease of 22.2% compared to CNY 1,669,609,011.22 in the same period of 2022[24]. - The net cash flow from operating activities in Q3 2023 was CNY 145,614,894.49, up 5.4% from CNY 138,125,272.35 in Q3 2022[25]. - Total cash outflow from operating activities in Q3 2023 was CNY 1,261,315,928.87, down 24.5% from CNY 1,671,808,671.90 in Q3 2022[25]. - The net cash flow from investing activities in Q3 2023 was -CNY 84,230,977.05, an improvement from -CNY 163,082,776.47 in Q3 2022[25]. - Cash inflow from financing activities in Q3 2023 was CNY 149,133,100.12, significantly lower than CNY 480,388,766.85 in Q3 2022[26]. - The net cash flow from financing activities in Q3 2023 was -CNY 369,269,914.53, compared to a positive net flow of CNY 130,313,798.82 in Q3 2022[26]. - The total cash and cash equivalents at the end of Q3 2023 was CNY 1,054,783,730.00, down from CNY 1,236,468,311.92 at the end of Q3 2022[26]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,759[10]. - The largest shareholder, Lin Qi, holds 25.11% of the shares, totaling 34,900,230 shares[10]. Legal Matters - The company is currently involved in a legal dispute with a claim for economic damages of RMB 99 million related to patent infringement[12]. - The company has taken actions to actively respond to the lawsuit and is contesting the claims made by the plaintiff[13]. Inventory and Costs - The company reported a significant reduction in inventory, which decreased to RMB 167,777,464.37 from RMB 205,227,948.56, a decline of approximately 18.2%[14]. - Total operating costs for the first three quarters of 2023 were CNY 1,146,125,766.88, down 19% from CNY 1,422,054,592.18 in 2022[20]. - Research and development expenses for the first three quarters of 2023 were CNY 59,424,399.03, down from CNY 70,003,833.97 in the same period of 2022[20]. Other Financial Metrics - The weighted average return on equity was 2.43%, an increase of 0.28 percentage points compared to the previous year[5]. - The company achieved an investment income of CNY 24,529,034.40 in the first three quarters of 2023, significantly higher than CNY 9,950,483.06 in the same period of 2022[20]. - The company reported a financial income of CNY 12,553,774.04 for the first three quarters of 2023, compared to a loss of CNY 25,541,159.68 in the same period of 2022[20]. - The company experienced a foreign exchange gain of CNY 32,893,242.60 in Q3 2023, compared to CNY 21,867,302.08 in Q3 2022[26].